Dolly Parton’s estate announced that the music icon died following a “brief battle with cancer.”

After Parton’s nephew Bryan Seaver shared the news of her passing at the age of 80 in a video message uploaded to her Instagram account Aug. 25, 2026, her estate shared more details about her health struggles.

“After bravely facing a brief battle with cancer, Dolly departed her Earthly life today at the Vanderbilt-Ingram Cancer Center surrounded by loved ones,” Parton’s estate said in a statement.

The statement also praised Parton for living a life filled with philanthropy and kindness.

“Our beloved Dolly Parton spent her life and career bringing joy, laughter, hope and integrity into everything she touched. Her unmatched generosity reached the lives of countless people whom she would never meet, yet she was always there to offer a helping hand,” the statement read.

“Whether it be the hundreds of millions of books donated through her invaluable Imagination Library or funding research that helped create a lifesaving vaccine used around the world, Dolly’s unconditional love for all people was the guiding force for her lasting impact.”

The estate signed the statement “Team Dolly.”

Parton’s sister Stella also referenced her cancer battle in a tribute shared Aug. 27.

“My sister was one of the most generous, thoughtful and kind people I’ve ever known,” she wrote.

“What the world saw is exactly who she was, so much so, she told me recently that if there was no hope for her, she would still allow her medical team to try experimental drugs in the hope of helping others in the future.”

Parton had not publicly shared that she was diagnosed with cancer prior to her death. However, she had informed fans that she had health struggles prior to her death.

What Was Dolly Parton’s Cause of Death?

Parton’s estate confirmed in a statement that she had faced “a brief battle with cancer” before she died. The estate said she died on Aug. 25 at Vanderbilt-Ingram Cancer Center with her loved ones by her side.

Fans were aware that Parton had been dealing with health challenges about a year before she died.

In September 2025, she announced that she needed to cancel her Las Vegas residency shows to address “health challenges.”

Earlier this year in March, she spoke more about her “few little health issues” at the opening day celebration for Dollywood’s 41st season.

“I just kind of got worn down and worn out, grieving over Carl and a lot of other little things going on,” she said regarding the death of husband Carl Thomas Dean in March 2025.

“I just got myself kind of where I needed to build myself back up spiritually, emotionally and physically. But, all is good. It didn’t slow me down,” she added.

She shared additional details in a video uploaded to Instagram in May.

“The good news is I’m responding really well to meds and treatments, and I’m improving every day. Now, the bad news is it’s going to take me a little while before I’m up to stage-performance level,” she told fans.

What Kind of Cancer Did Dolly Parton Have?

The statement from Team Dolly did not specify what kind of cancer she had.

What Did Dolly Parton’s Family Say About Her Death?

Seaver, the son of Parton’s sister Cassie Parton, previously shared in his video that his aunt asked him to record the message before he “fully absorbed it as a future reality.” He said fulfilling her request was “honor that is mixed with absolute pride and great sadness.”

“Our family and the team she has entrusted with her legacy will work diligently to ensure her spirit will live with us forever. Dolly was a farmer, just like her daddy,” Seaver shared.

“He farmed the soil. She farmed songs and happiness. Dolly called me and said she wants to rest in a beautiful bed of plush cotton because after a life wearing heavy rhinestones, she finally deserves to be comfortable and have some rest.”

Parton’s goddaughter, Miley Cyrus, honored Parton with a tribute during an October 2026 performance at the Hollywood Bowl. The venue is the only place Cyrus had ever seen her “Aunt Dolly” perform live.

Before Cyrus sang her rendition of Parton’s “Jolene,” she tearfully addressed the audience. “Me and Dolly, we are eternal,” Cyrus said, seated at the edge of the stage. “Nothing in this life could ever tear us apart.”

“And I’m gonna see her again,” Cyrus went on. “And I can’t f------ wait. And I miss her.”

Other tributes to the music icon poured in following Parton’s passing. TODAY’s Jenna Bush Hager shared a heartfelt message, as did Kelly Clarkson, Parton’s “9 to 5” co-stars Lily Tomlin and Jane Fonda, Patti LaBelle and more.

Vanderbilt Health also honored Parton’s legacy, including her numerous financial contributions to both children’s cancer and infectious disease research. A $1 million contribution from the singer helped fund Moderna’s COVID-19 vaccine.

PayCargo announces an ongoing partnership with AREAS Foundation, a Spain-based non-profit focused on supporting the social inclusion and personal and professional development of people at risk of exclusion through educational and training programs. The partnership reflects both organizations’ longstanding values centered around ethics and service, as they approach several meaningful projects in 2026.

AREAS Foundation programming is built to support quality education in a safe, healthy environment. The organization offers a Scholarship Program which funds school fees, transportation, accommodation, and other necessary expenses so that children with good academic results, but insufficient financial means, can pursue their studies. They also tackle Construction Projects, providing full funding for new or improved educational facilities.

Eduardo Del Riego, Global CEO, PayCargo said: “We’re thrilled to work with AREAS Foundation towards our shared goal of empowering individuals with critical tools to improve their quality of life. We look forward to growing our partnership and deepening PayCargo’s involvement, working toward making lasting positive changes within vulnerable communities.”

In 2026, the scholarship program has 110 active scholarships, directly benefiting over 1,000 individuals across India, Cameroon, Kenya, Uganda, Rwanda, Gambia, and Spain. The program grants these scholarships to students at several levels, including early childhood, elementary and secondary education, and university.

Two construction projects, which kicked off earlier in 2026, will impact over 35,000 individuals. Phase one of the construction project in Kenya involves building a Rescue Dormitory for girls fleeing genital mutilation and child marriage, providing a safe place to live where they can focus on their studies. This phase is expected to take one year before moving on to phases two and three, which will ultimately aim to further improve education, safety, and health in the rural community. The second construction project, in Nigeria, is focused on building a new facility for students at the Holy Name School, which is in danger of collapse and, at the same time, cannot accommodate its growing demand for enrollment. The new school will have updated conditions and the space necessary to provide quality education for its students.

Gabriel Novela del Rey, President, AREAS Foundation said: “Global impact is woven into our work, and we’re glad to have an internationally recognized partner in PayCargo. Their support enables us to both make headway with our projects and reach more people and organizations, bringing awareness to our vision.”

Visit https://www.fundacionareas.org/en/ to learn more about the invaluable work at AREAS Foundation. For more information on PayCargo and the other causes it supports, visit https://paycargo.com/community/.

About PayCargo:

PayCargo is the most trusted logistics payment platform, accelerating the release of cargo across the global supply chain. With over 6,500 active vendors in the PayCargo Network, users can instantly send secure payments for same-day or overnight release to major air, land, rail, and ocean carriers.

What started as a streamlined payment solution has grown into a comprehensive platform supporting the full invoice lifecycle. By expanding beyond payments to offer tools that automate and optimize invoice processing, PayCargo continues to drive innovation across the supply chain, helping industry leaders improve efficiency, reduce manual work, and gain better financial control.

About AREAS Foundation:

AREAS Foundation: Action and Resources for Education, Advancement, and Solidarity aims to contribute to the social inclusion and the personal and professional development of people at risk of exclusion through educational and training programs. It seeks to empower its beneficiaries by providing them with the necessary tools to reach their full potential and improve their quality of life and that of those around them, with the goal of contributing to a more just and equitable society.

Image Source: Fred Guerdin E-COMMERCE FORUM

PayCargo was on the ground in Liège for the 2026 EU Cross-Border E-commerce Forum (EU-CBEC), hosted at the Palais des Congrès by Liège Airport (LGG) and the Wallonia Export-Investment Agency (AWEX). It was two days of strong conversations, informative panels, and a clear direction on where cross-border e-commerce and air cargo are heading.

Three insights stood out, and they’re shaping how PayCargo is thinking about the road ahead for e-commerce, air cargo, and customs.

1. The EU’s new low-value customs duty is redirecting trade, not collapsing it

The overarching theme of the forum was the EU’s removal of its duty exemption on low-value goods: as of July 2026, member states introduced a €3 customs duty per item on e-commerce parcels valued below €150, aimed at leveling the playing field as low-cost, high-volume platforms flooded the market with duty-free imports.

The effects are showing up fast in the data. China/Hong Kong–Europe freighter capacity fell sharply between June and August, with Budapest down 58%, Liège down 35%, and Schiphol down 28%. Ryan Keyrouse of data company Rotate presented in Liège and named Budapest, Liège, Urumqi, and Hong Kong as the e-commerce gateways where the declines are most concentrated. Liège Airport itself reported e-commerce parcel volumes down 24% year-over-year, with customs declarations down 52% — though total cargo tonnage was still up 4% on the strength of pharma, data center equipment, and flowers.

Keyrouse’s data also points to something more nuanced than a straight decline. US and Brazilian e-commerce volumes have already recovered after similar changes to their low-value import exemptions, and global e-commerce air cargo volumes in July 2026 were still 23% higher than two years prior. So, the demand hasn’t disappeared; it’s being redirected to wherever the rules are least restrictive.

2. Reaction speed has become the operative question for air freight

Panelists described a shift in the cadence of disruption: where a trend used to move meaningful volume once every four or five months, forum discussion suggested that new demand shifts and capacity reallocations are now happening every two to three weeks. This was raised as a panel observation rather than a hard data point, but the carrier response backs it up — within a single month, Air China Cargo cut 25 weekly flights to Europe, bringing its total to 35 per week, while China Central Airlines reduced its schedule from 30 to 20 flights and CMA CGM cut from 12 to 3.

France offered a preview of what’s coming EU-wide: volumes there fell 30% in March when it introduced its own charge ahead of the EU levy, deepening to a 64% decline by July. And the regulatory pressure isn’t finished — a separate €2 per-consignment handling fee takes effect November 1, 2026, bridging to the EU Customs Data Hub in 2028, with individual member states layering on their own fees in the meantime. For forwarders and carriers on Far East–Europe lanes, planning around stable, predictable flows is no longer realistic.

3. E-commerce and AI cargo, once air freight’s two growth engines, are pulling apart

For years, e-commerce and AI/data center buildout drove air cargo growth together. That’s no longer the case. As one vertical loses ground in Europe, the other is pulling capacity toward the US.

Maarten Wormer of Aevean presented the numbers: US-bound, data center-related air imports rose 103% year-over-year over the first seven months of 2026, reaching 107,000 tons in July — roughly 1,000 freighter flights. Within that, servers were up 181%, network equipment up 130%, and computer components up 86%. Overall air cargo demand was up 5.8% year-to-date, led by Asia Pacific–North America lanes (+24%), while Asia Pacific–Europe grew just 4%.

The pattern holds at the country level. Asia–US demand is leaning heavily on AI-related exports out of Taiwan, South Korea’s load factors to the US are running near 90%, and Taiwan, South Korea, Malaysia, Thailand, and Singapore are now among the tightest airfreight markets globally — even as ex-China–US demand stays soft. It’s the same divergence in miniature: one vertical redirecting, one accelerating, and both demanding a level of agility the industry is still adjusting to.

PayCargo thanks the EU CBEC and AWEX teams for a well-organized forum, and the wider community of attendees for their perspectives throughout the event.

Meet PayCargo at a future event.

Lindstrom is the founder and an Attending Surgeon at Minnesota Eye Consultants and an Adjunct Professor Emeritus at the University of Minnesota, Department of Ophthalmology. He is a board-certified Ophthalmologist and an internationally recognized leader in corneal, cataract, refractive and laser surgery.

Most Recent

We’re sorry, but an unexpected error has occurred.

Please refresh your browser and try again. If this error persists, please contact ITSupport@wyanokegroup.com for assistance.

You need

{credits} Credits

to reach your goal.

Because The Wyanoke Group subsidiary companies of Healio, Healio Strategic Solutions, Healio Live, Vindico Medical Education and SLACK Incorporated, report on emerging technologies, techniques and medical therapies, some print and online reports may discuss drug and device applications that either are not approved by regulatory agencies and/or are not considered to be within the standard practice of medicine.

Content is intended for informational purposes only and should not be used as the basis of patient treatment. All opinions expressed by authors and quoted sources are their own and do not necessarily reflect the opinions of the editors, publishers or editorial boards of The Wyanoke Group subsidiary companies. The acceptance of advertising in no way implies endorsement by the editors, publishers or editorial boards of The Wyanoke Group subsidiary companies. Thank you.

Reminder from

Healio CME

You're almost at

{percent}%

completed.

Keep it going!

Your deadline is here.

An actual case challenging the reader to make the diagnosis based on clinical findings.

Reminder from

Healio CME

You need

{credits} Credits

to reach your goal.

Reminder from

Healio CME

You're almost at

{percent}%

completed.

Keep it going!

Reminder from

Healio CME

Your deadline is here.

You need

{credits} Credits

to reach your goal.

Would you like to receive email reminders to complete your saved activities from Healio CME?

Activity saved! You'll receive reminders to complete your saved activities from Healio CME.

You're logged in as .

Please review your account details and complete any missing fields.

Not you? Log out

A closer look at drug discoveries and developments that affect clinical practice.

Reminder from

Healio CME

You need

{credits} Credits

to reach your goal.

Reminder from

Healio CME

You're almost at

{percent}%

completed.

Keep it going!

Reminder from

Healio CME

Your deadline is here.

You need

{credits} Credits

to reach your goal.

Would you like to receive email reminders to complete your saved activities from Healio CME?

Activity saved! You'll receive reminders to complete your saved activities from Healio CME.

You're logged in as .

Please review your account details and complete any missing fields.

Not you? Log out

News from Apex Media Partners A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Making a selection with these dropdown will cause content on this page to change. News listings will update as each option is selected.

Latest

Journalists and Bloggers

The news you need, when you need it.

Join PR Newswire for Journalists to access all of the free services designated to make your job easier.

In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.

LEARN MORE

Amplify Your News With the Reach, Visibility and Engagement It Deserves

Distribute news through a trusted global network that helps your content reach journalists, news sites, search engines and AI-powered discovery platforms, maximizing visibility wherever audiences search for information.

Everything You Need to Distribute Your Press Release

Upload your press release

Our editorial team—available 24/7—proofreads every news release for grammar, spelling, punctuation, broken links, proper tagging for your target industries and SEO-related guidelines to optimize your immediate and long-term search performance along with other public relations best practices.

Choose your target audience

Target by countries (more than 170 in over 40 languages), states or provinces, regions, cities, industries, verticals, beats (e.g., tech, IR, etc.), demographics and more.

Send it — and track the results

Track impressions, site postings and more for every native ad and article you place. Get the analytics you need to demonstrate effectiveness and fine-tune your next campaign.

Add multimedia to maximize engagement

Press releases that include multimedia generate up to 6x greater engagement. PR Newswire’s press release distribution platform allows you to quickly upload photos, videos, logos, infographics, and other dynamic content. Easily organize and embed multimedia content into your press releases. Share your visuals on the industry’s largest multimedia newswire and display them on thousands of syndicated websites.

Only PR Newswire can get your news to 440,000+ newsrooms, direct feeds and subscribers, including 270,000+ journalists and influencers and 9,000+ websites and digital media outlets.

440,000+ Newsrooms, Websites, Direct Feeds, Journalists and Influencers

With more than 70 years of innovation in news distribution, we connect your stories to a global network of newsrooms in minutes. Reach print, radio and TV outlets, financial portals, trade publications and other media across the world.

9,000+ Digital Media Outlets

Reach major media websites, financial portals, trade pubs, search engines and blogs through our online syndication network. And leverage our multimedia and social media distribution channels to maximize your visibility and engagement opportunities.

270,000+ Journalist Inboxes

Only PR Newswire sends your story to an exclusive, opt-in community of journalists, bloggers and influencers that covers nearly 200 news beats and industry verticals. They count on our dynamic online portal and customizable email updates for story leads—including yours.

"Reach is critical to our big releases, which is why we use PR Newswire. Getting into all of the tiny publications—these are the news outlets and the local papers that a lot of our customers read.”

VP of Comms, Large Private B2C Company

Put Your News in Trusted Hands

Credibility that gets you published and shared

Media and journalists reference PR Newswire content 36% more often than content from our nearest competitor! Editors, journalists and influencers worldwide know that content from PR Newswire is credible, reliable, worth reading and worth sharing.

Security and accuracy that protects your business and reputation

We are committed to safeguarding customers' sensitive data. PR Newswire is compliant with SOC 2 Type II, the most comprehensive and rigorous security standard for third-party cloud services. And when it comes to your content, we treat that with just as much importance. Our editorial team reviews over 325,000 press releases annually and in 2022 caught over 22,000 mistakes in client copy.

What makes PR Newswire different from other press release distribution services?

PR Newswire has the industry’s largest global distribution network with direct connections to journalists, media outlets, influencers and various digital publication platforms, helping brands reach verified audiences at scale.

How much does it cost to distribute a press release with PR Newswire?

Costs vary based on distribution scope, geographic reach and additional services such as multimedia, targeting and amplification channels.

Why do journalists trust PR Newswire?

Journalists rely on PR Newswire for timely, verified and professionally formatted news that is easy to access, cite and share.

Can PR Newswire help me reach specific industries or audiences?

Yes. PR Newswire offers targeting options by geography, industry and audience, helping ensure your news reaches the most relevant recipients.

What types of announcements perform best on PR Newswire?

High-impact announcements such as product launches, partnerships, earnings reports, research findings and major company updates tend to generate the strongest visibility and engagement.

How quickly will my press release be distributed?

Once you have an established PR Newswire account, press releases can be distributed within hours of approval, allowing brands to share timely news and respond quickly to market opportunities.

How does PR Newswire support SEO, AEO and GEO strategies?

PR Newswire supports visibility across traditional search and AI platforms through its high domain authority, combined with distributing structured, authoritative content that can be indexed, cited and surfaced in both traditional and AI-driven results.

Does PR Newswire provide analytics or reporting?

Yes. PR Newswire provides performance insights such as visibility, engagement and reach to help measure the impact of your press release.

Can multimedia be included in my press release?

Yes. PR Newswire supports images, videos and other multimedia elements to increase engagement and improve storytelling.

What is the value of using a trusted newswire like PR Newswire?

Using a trusted newswire enhances credibility, expands reach beyond owned channels, and increases the likelihood of media pickup and third-party validation.

How does PR Newswire compare to posting a press release on my own website?

Publishing on your own site limits reach, while PR Newswire distributes your content across a broad network of media and digital platforms to maximize visibility and impact.

Can small and mid-sized businesses benefit from PR Newswire?

Yes. PR Newswire helps organizations of all sizes increase visibility, build credibility and reach new audiences through professional distribution.

How does PR Newswire help build brand authority online?

By distributing news across trusted third-party sites and media outlets, PR Newswire helps establish your brand as a credible and widely referenced source of information.

How does PR Newswire support multichannel visibility?

PR Newswire enables brands to extend a press release across multiple platforms—including media outlets, websites, social channels, paid placements and digital publications—to maximize reach and engagement.

How long does it take to see results from PR Newswire press release distribution?

Results can include immediate search visibility and pickup within hours, with longer-term benefits such as media coverage and brand awareness developing over time.

How do I measure the success of a press release distributed through PR Newswire?

Success can be measured through metrics such as visibility in search and AI-generated results, impressions, website traffic engagement and media pickup.

I’d like to receive expert insights, product news, and event invitations from Cision and its affiliated brands.

I can unsubscribe at any time.

By submitting your information, you agree that Cision may process your personal data to complete this request. For more information, please see our Privacy Notice.

By submitting your information, you agree that Cision and its affiliated brands, including Brandwatch, CisionOne, and PR Newswire, may contact you with marketing communications. For more information, please see our Privacy Notice.

A drug approved to treat type 2 diabetes can have another striking effect on the body: significant weight loss in people with obesity.

Once-weekly injections of tirzepatide provided “substantial and sustained reductions in body weight,” researchers reported in The New England Journal of Medicine over the weekend.

“We need this tool in the toolbox. There is vastly disproportionately less treatment for obesity as a chronic disease than other chronic diseases,” NBC news medical contributor Dr. Natalie Azar said.

“It’s so important and so relevant. The majority of Americans are either overweight or obese.”

About 9 out of 10 people with obesity lost weight while taking tirzepatide in this study, said Dr. Ania Jastreboff, the lead author and director of weight management and obesity prevention at the Yale Stress Center in New Haven, Connecticut.

"I was very impressed. I don’t think that many of us expected those types of results," Jastreboff told TODAY.

"I think (it's) very exciting," added Dr. Robert Gabbay, chief science and medical officer at the American Diabetes Association.

"We always knew obesity is important and has a profound impact on diabetes and most people with type 2 diabetes have obesity. But the tools to address obesity have not been as potent as what we saw here."

More than 2,500 adults with either a BMI of 30 or more, or a BMI of 27 or more and at least one weight-related complication, took part in a phase 3 double-blind, randomized, controlled trial. It compared three different doses of tirzepatide with a placebo. None of the participants had diabetes.

In addition to the drug, participants also received lifestyle interventions that included counseling sessions to help them eat healthy, balanced meals with a deficit of 500 calories per day, and exercise for at least 150 minutes per week.

After almost a year and a half, the participants lost on average of:

- 5 pounds on the placebo

- 35 pounds on the lowest dose of tirzepatide (5 milligrams)

- 49 pounds on the medium dose (10 milligrams)

- 52 pounds on the highest dose (15 milligrams)

The results are comparable to those doctors see with gastric bypass surgery, Azar noted, and higher than what has been observed with other drugs currently available on the market to treat obesity.

The clinical trial was financially supported by Eli Lilly, the maker of the drug.

More than 40% of American adults are considered obese, according to the Centers for Disease Control and Prevention.

Obesity treatment has traditionally focused on lifestyle changes, but obesity is a “complex” metabolic disease that makes it difficult to return to a lower weight without extra help, such as anti-obesity medications, the authors of the study wrote.

Our bodies evolved to prevent starvation, said Jastreboff, who serves on the scientific advisory board for Eli Lilly. They will do whatever they can to hold on to extra fat, so that if there’s a famine, we will not die.

That system is also impacted by a modern world where people live sedentary lifestyles, often experience stress and a lack of sleep, and have lots of tasty food readily available at all hours. Obesity results from the dysregulation of how much fat our body wants to carry — a setpoint determined by our brain, she noted.

"The goal of these anti-obesity medications is to reset that setpoint. So basically our body wants to carry less weight, specifically less fat," Jastreboff said.

"The 'tides' are shifting, and there are now more options for people with obesity to lose weight," researchers added in an accompanying editorial in The New England Journal of Medicine.

The drug tested in the trial affects two important hormones that impact several areas of the body, Azar said. In the pancreas, it increases the release of insulin to reduce the patient's blood sugar levels. It also helps to suppress appetite and slows how fast the stomach is emptying so the patient feels full faster.

"One of the important things of using the medicine is to have people be more mindful of their eating, to take a moment and realize, ‘Oh yes, I am full. I don’t need to keep eating,'" Gabbay noted.

Patients inject the drug themselves into their abdomen or their arm. "It takes 30 seconds once a week... it’s very easy," Jastreboff said.

When it came to side effects, the drug was tolerated well, Azar said. The most frequently reported issues were gastrointestinal symptoms, such as nausea, diarrhea and constipation. More trials will be done, and more are already underway, Jastreboff said.

Patients will have to stay on the medicine for it to keep working in the same way people who receive medication for high blood pressure must keep taking it, even when their hypertension improves, Jastreboff said.

"When you stop that medicine, their weight goes back up and we should not be surprised because obesity is a chronic disease just like any other chronic disease. We have to treat it. We have to continue treating it," she noted.

Last month, the U.S. Food and Drug Administration approved tirzepatide as Mounjaro, a treatment for adults with type 2 diabetes. It has not yet been approved as an obesity treatment.

“We are looking forward to reviewing tirzepatide data with the FDA and discussing a potentially expedited path forward, and we should have an updated timeline by the end of the year,” said Maggie Pfeiffer, associate director of strategy and operations at Lilly Diabetes.

But the drug won’t ever be a substitute for diet and exercise, Azar cautioned.

"We do not have a pill or an injection that can help people make healthier food choices or eat healthfully or move more," Jastreboff agreed. "So it’s critical as patients are losing weight that we help them do so in a way that really highlights the importance of making healthy food choices and making sure that they’re incorporating movement into their daily lives."

The drug is also likely to be expensive: Tirzepatide approved for diabetes costs about $1,000 a month, Azar noted. Lilly is offering savings cards to reduce patient out-of-pocket costs, Pfeiffer said.